8-K - AVNS - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: January 11, 2022

(Date of earliest event reported)

AVANOS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Commission file number 001-36440

Delaware				46-4987888
(State or other jurisdiction of incorporation)				(I.R.S. Employer Identification No.)
	5405 Windward Parkway
	Suite 100 South
	Alpharetta,	Georgia	30004
	(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (844) 428-2667

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock - $0.01 Par Value	AVNS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 11, 2022, Avanos Medical, Inc. (the “Company”) posted an investor presentation to its website at https://avanos.investorroom.com/. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The presentation will be used by the Company in its prepared remarks at the J.P. Morgan Healthcare Conference. The presentation indicates that the Company’s 2021 adjusted earnings per share (“EPS”) will likely fall below the $1.10 to $1.20 per share guidance previously provided, as improved gross margins will finish short of expectations during the three months ended December 31, 2021. However, that statement does not take into account certain expected tax benefits. Inclusive of the additional expected tax benefits, the Company still anticipates EPS for the year ended December 31, 2021 to be in the guidance range of $1.10 to $1.20 per share.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.	Description
99.1	J.P. Morgan Healthcare Conference presentation
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AVANOS MEDICAL, INC.
Date:	January 11, 2022	By:	/s/ S. Ross Mansbach
			S. Ross Mansbach<br>Vice President, Deputy General Counsel and Corporate Secretary

a2022jpmorganhealthcarec

1 J.P. MORGAN HEALTHCARE CONFERENCE JOE WOODY CHIEF EXECUTIVE OFFICER JANUARY 11, 2022

2 FORWARD-LOOKING INFORMATION NON-GAAP FINANCIAL MEASURES Certain matters in this presentation and webcast, including expectations and planning assumptions and any estimates, projections, and statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitute forward-looking statements and are based upon management’s expectations and beliefs concerning future events impacting the Company. These statements are subject to risks and uncertainties, including currency exchange risks, cost savings and reductions, raw material, energy, and other input costs, risks related to the ongoing COVID-19 pandemic, competition, market demand, economic condition, IT matters, availability of drugs used in our Acute Pain products, other supply chain disruptions and legislative and regulatory actions. There can be no assurance that these future events will occur as anticipated or that the Company’s results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them. For a more complete listing and description of other factors that could cause the Company’s future results to differ materially from those expressed in any forward-looking statements, see the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Management believes that non-GAAP financial measures enhance investors’ understanding and analysis of the Company’s performance. As such, results and outlook have been adjusted to exclude certain items for relevant time periods as indicated in the non-GAAP reconciliations to the comparable GAAP financial measures included in this presentation and release posted on our website (www.avanos.com/investors).

3 WHO WE ARE ~$740M+ Global Revenue* Pain Management Chronic Care Diversified portfolio with 8 market-leading products in the U.S. International Business operations in 90+ countries U.S. Creating Shareholder Value ~$10B Addressable Market Optimized cost structure M&A execution and integration Organic growth acceleration *Est. 2021 figure Our Vision: To be the best at getting patients back to the things that matter

4 1970s - 2014 2014 2016 2018 2019 2020 • Completed spin-off as Halyard Health • Acquired CORPAK Medsystems • Acquired NeoMed, Summit and endOclear 2021 • Announced intent to acquire OrthogenRx (anticipated close in January 2022) • Launched stock repurchase program • Deliver revenue growth and margin expansion • Announced Surgical & Infection Prevention business divestiture • Rebranded as Avanos Medical • Acquired Game Ready OUR EVOLUTION • Heightened focus on commercial execution and M&A Integration • Increased response to global pandemic • Kimberly-Clark established Health Care surgical supplies business • Entered medical device business with Ballard Medical, Baylis Medical, and I-Flow Corporation acquisitions

EXECUTION ✓ Strong sales performance – will meet growth guidance metrics (2 – 4%) ✓ Effective OPEX management reduced SG&A; partially offsetting COGS ✓ Efficient capital deployment with M&A and share repurchase ✓ Retired significant legal matters providing additional clarity to 2022 Free Cash Flow ✓ Well-positioned for strong execution in 2022 ❖ Supply chain / gross margin challenges ❖ Elective procedures / healthcare access – slower return with additional variants ❖ Adjusted EPS likely to fall below $1.10-$1.20 guidance as improved gross margins will finish short of Q4 expectations Our teams continued to demonstrate resilience in response to the pandemic’s changing dynamics. We are confident in our ability to execute our strategy in 2022 and beyond. 5 2021 IN REVIEW CHALLENGES Through our challenges, we remained focused on getting patients back to the things that matter as we met customers’ needs. We are confident these headwinds are transitory.

6 Our Franchises

7 CHRONIC CARE Leading market positions enhanced by bolt-on acquisitions Addressable Market Product Portfolio ~$400M Respiratory Health ~$1B Digestive Health Long-term Feeding Nasogastric Feeding Neonatal Feeding Closed Suction Continued market leadership with launch of MIC-KEY* SF in 2020 Demonstrated capability with leading position in nasogastric feeding Avanos enters into the neonatal market, a leading organic growth opportunity Enhances Respiratory Health portfolio and leverages existing sales and marketing infrastructure Mic-Key Corpak (2016) NeoMed (2019) endOclear (2019) Digestive Health Respiratory Health

8 PAIN MANAGEMENT Delivering non-opioid pain relief therapies Addressable Market Product Portfolio >$4B Interventional Pain >$4B Acute Pain 100M >20M Target U.S. surgical procedures Americans in chronic pain ON-Q Summit Medical (2019) Game Ready (2018) Clinically proven non-opioid therapy to reduce post-surgical pain Electronic ambulatory pumps Market-leading provider of cold and compression therapy system COOLIEF* COOLIEF* Technology Innovation (2020) OrthogenRx (2022) Only FDA-cleared RF treatment for OA knee pain Cooled and standard radiofrequency generator Intra-articular injections for OA knee pain

9 2022 and Beyond

10 WELL-POSITIONED TO DELIVER SALES GROWTH IN ATTRACTIVE MARKETS GROSS AND OPERATING MARGINS TO IMPROVE THROUGH 2022 FOUR AREAS OF VALUE CREATION ✓ Leverage market-leading positions in Digestive Health, Respiratory Health and Acute Pain leading to 3%-6% organic growth ✓ Maintain double-digit growth in COOLIEF* ✓ Grow market share in alternate sites (e.g., ASC setting) ✓ Expand NeoMed adoption through ENFit conversions ✓ Execute on OrthogenRx integration ✓ Improve manufacturing efficiency; minimize inflation impacts ✓ Reduce transportation costs ✓ Advance SKU rationalization, demand planning opportunities ✓ Maintain OPEX discipline and cost containment controls 2 1 DELIVERING VALUE TO ALL STAKEHOLDERS

11 FOCUS ON CAPITAL DEPLOYMENT USING STRONG BALANCE SHEET POSITION TO SUPPLEMENT ORGANIC GROWTH IMPROVED MARGINS AND MATERIALLY FEWER ONE-TIME ITEMS WILL GENERATE FREE CASH FLOW ✓ Execute additional bolt-on acquisitions to enhance portfolio ✓ Identify opportunities to optimize portfolio ✓ Complete $30m stock repurchase program ✓ Ended 2021 with ~$115m in cash and $130M in debt; 2022 acquisition capital >$350M (post OrthogenRx closing) ✓ Meaningful margin expansion in 2022 combined with solid top-line growth ✓ Significantly less cash usage related to recently retired litigation and other one-time costs ✓ Anticipate delivering at least $70m of free cash flow in 2022 3 4 FOUR AREAS OF VALUE CREATION DELIVERING VALUE TO ALL STAKEHOLDERS

12 The best at getting patients back to the things that matter